Models of Chronic Obstructive Pulmonary Disease V1.0
Research type
Research Study
Full title
A pilot study to develop laboratory models of the airway using multiple primary cell types from individual patients with COPD.\n
IRAS ID
243156
Contact name
Frank McCaughan
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
0 years, 10 months, 30 days
Research summary
The purpose of this study is to develop new cell cultures and try to create laboratory models of lung disease. The hope is that these will be useful in testing new treatments. The cells and culture systems will be shared with academic and industry colleagues in the UK and abroad to increase our chances of success and of developing new treatments. \n\nThe Key Question\nCan we develop laboratory models of airways disease that represent a patient’s disease and can be used to develop new treatments?\n\nWhat are we going to do to answer this question?\nCells removed from patients will be grown in the laboratory and used for experiments including molecular tests and changing the levels of genes of interest or altering their function. We will then assess whether the cells taken from the airway are different between patients, and by working with academic and industry colleagues we will be able to test treatment options. \n\nWhy is this study important?\nCurrently available treatments for COPD often don’t work very well. There is a huge need to make more effective treatments that match individual patients’ needs.\n\nWhat is the procedure and the associated risks?\nPatients who are undergoing flexible bronchoscopy as part of routine care will be invited to have extra samples taken. These will include samples of the airway wall (biopsies), and airway cells (by brushing the wall) and a single blood test. These are routine procedures and the risk of significant complications is very low (less than 1%).\n\nWho will be recruited and where?\nPatients with COPD who will be having a bronchoscopy as part of their care in the COPD service of Cambridge University Hospitals NHS Trust will be recruited. [COVID-19 amendment 04/05/2020] Extending the study from bronchial epithelium from participants with COPD to include the significantly less invasive nasal epithelium from patients with COVID-19 and control patients. - The amendment proposes using a brush and a mini-biopsy of the lining of the nasal cavity.\nAs some patients with severe disease will be on the intensive care unit the applicant seeks to invite participation from those who cannot consent for themselves.\nParticipants who are inpatients who do not have COVID-19 will be invited to enrol and undergo a nasal brush and mini-biopsy. \nThe exclusion criteria have been changed to reflect the new proposed inpatient participants with COVID-19.\nAddition of Royal Papworth as a site \n
REC name
South West - Frenchay Research Ethics Committee
REC reference
19/SW/0152
Date of REC Opinion
22 Oct 2019
REC opinion
Further Information Favourable Opinion